Abstract
Background Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, guidance (“Japanese Guide”) has been published by a working group of several academic societies and announced by the Ministry of Health, Labour, and Welfare. Steroids as a candidate treatment for COVID-19 were noted in the Japanese Guide. However, the prescription details for steroids, and whether the Japanese Guide changed its clinical practice, were unclear. This study aimed to examine the impact of the Japanese Guide on the trends in the prescription of steroids for COVID-19 inpatients in Japan.
Methods We selected our study population using Diagnostic Procedure Combination (DPC) data from hospitals participating in the Quality Indicator/Improvement Project (QIP). The inclusion criteria were patients discharged from hospital between January 2020 and December 2020, who had been diagnosed with COVID-19, and were aged 18 years or older. The epidemiological characteristics of cases and the proportion of steroid prescriptions were described on a weekly basis. The same analysis was performed for subgroups classified by disease severity.
Results The study population comprised 8603 cases (410 severe cases, 2231 moderate II cases, and 5962 moderate I/mild cases). The maximum proportion of cases prescribed with dexamethasone increased remarkably from 2.5% to 35.2% in the study population before and after week 29 (July 2020), when dexamethasone was included in the guidance. These increases were 7.7% to 58.7% in severe cases, 5.0% to 57.2% in moderate II cases, and 1.1% to 19.2% in moderate I/mild cases. Although the proportion of cases prescribed prednisolone and methylprednisolone decreased in moderate II and moderate I/mild cases, it remained high in severe cases.
Conclusions We showed the trends of steroid prescriptions in COVID-19 inpatients. The results showed that guidance can influence drug treatment provided during an emerging infectious disease pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by JSPS KAKENHI Grant Number JP19H01075 to Yuichi Imanaka and JP21K21136 to Jung-ho Shin from the Japan Society for the Promotion of Science and Health Labour Sciences Research Grant Numbers JPMH20HA2003 and JPMH21IA1005 by the Ministry of Health, Labour and Welfare, Japan to Yuichi Imanaka. The funders played no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The authors conducted the present study in accordance with the "Ethical Guidelines for Life Science and Medical Research Involving Human Subjects" issued by the Ministry of Education, Culture, Sports, Science, and Technology, the Ministry of Health, Labor, and Welfare, and the Ministry of Economy, Trade, and Industry. The present study was approved by the Ethics Committee, Kyoto University Graduate School and Faculty of Medicine (approval number: R0135).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Takuya Higuchi; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: higuchi.takuya.58c{at}kyoto-u.jp
Jung-ho Shin; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: shin.jungho.76v{at}kyoto-u.jp
Daisuke Takada; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: daisuke.gaotian{at}gmail.com
Tetsuji Morishita; Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: tmori{at}u-fukui.ac.jp
Susumu Kunisawa; Associate Professor, Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: kunisawa.susumu.2v{at}kyoto-u.ac.jp
Yuichi Imanaka; Professor, Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. E-mail address: imanaka-y{at}umin.net
First author’s surname: Higuchi
Data Availability
The information provided to waive consent from study subjects includes the list of data users. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The other contact points are Office of Research Promotion, General Affairs and Planning Division, Kyoto University (E-mail: kikaku06{at}mail2.adm.kyoto-u.ac.jp; Tel: +81-75-753-9301) and the Ethics Committee, Graduate School of Medicine, Kyoto University (e-mail: ethcom{at}kuhp.kyoto-u.ac.jp).
